Trial watch: Immunostimulatory cytokines Review uri icon


MeSH Major

  • Carrier Proteins
  • Immunity, Innate
  • Inflammasomes
  • Mitochondria


  • During the past two decades, the notion that cancer would merely constitute a cell-intrinsic disease has gradually been complemented by a model postulating that the immune system plays a relevant role during all stages of oncogenesis and tumor progression. Along with this conceptual shift, several strategies have been devised to stimulate tumor-specific immune responses, including relatively unselective approaches such as the systemic administration of adjuvants or immunomodulatory cytokines. One year ago, in the July issue of OncoImmunology, we described the main biological features of this large group of proteins and discussed the progress of ongoing clinical studies evaluating their safety and therapeutic potential in cancer patients. Here, we summarize the latest developments in this area of clinical research, focusing on high impact studies that have been published during the last 13 mo and clinical trials launched in the same period to investigate which cytokines can be employed as safe and efficient immunostimulatory interventions against cancer.

publication date

  • September 4, 2013



  • Review



  • eng

PubMed Central ID

  • PMC3782010

Digital Object Identifier (DOI)

  • 10.4161/onci.24850

PubMed ID

  • 24073369

Additional Document Info

start page

  • e24850


  • 2


  • 7